His primary areas of study are Internal medicine, Multiple myeloma, Bortezomib, Oncology and Surgery. His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Lymphoma and Phases of clinical research. His Multiple myeloma research is included under the broader classification of Immunology.
His Bortezomib course of study focuses on Thalidomide and Cyclophosphamide and Consolidation Chemotherapy. His biological study spans a wide range of topics, including Cancer, Predictive value of tests, Refractory and Daratumumab. His Surgery research incorporates themes from Subcutaneous injection and Immunopathology.
His scientific interests lie mostly in Internal medicine, Multiple myeloma, Oncology, Bortezomib and Surgery. His study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Beta-2 microglobulin. His Multiple myeloma research includes themes of Newly diagnosed, Cancer research, Regimen and Transplantation.
His Oncology research includes elements of Relapsed refractory, Carfilzomib, Refractory Multiple Myeloma and Daratumumab. His Bortezomib study which covers Waldenstrom macroglobulinemia that intersects with Macroglobulinemia and Clinical trial. His work on Melphalan as part of general Surgery study is frequently linked to Population, therefore connecting diverse disciplines of science.
His scientific interests lie mostly in Internal medicine, Oncology, Multiple myeloma, Dexamethasone and Daratumumab. His study in Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Newly diagnosed is carried out as part of his studies in Internal medicine. His Bortezomib research is multidisciplinary, incorporating perspectives in Thalidomide and Hazard ratio.
In the field of Oncology, his study on Autologous stem-cell transplantation overlaps with subjects such as In patient and Population. His studies in Multiple myeloma integrate themes in fields like Gastroenterology, Adverse effect, Refractory and Transplantation. His Dexamethasone study integrates concerns from other disciplines, such as Health related quality of life, Subgroup analysis and Tumor cells.
Xavier Leleu mainly focuses on Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. Internal medicine is often connected to Gastroenterology in his work. His study in the fields of Pomalidomide and Bortezomib under the domain of Multiple myeloma overlaps with other disciplines such as Population.
He has included themes like Health related quality of life and Quality of life in his Bortezomib study. He has researched Oncology in several fields, including Newly diagnosed, Early Relapse, Multicenter study and Transplantation. His Lenalidomide research is multidisciplinary, incorporating elements of Phases of clinical research and Surrogate endpoint.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht.
Lancet Oncology (2011)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Hervé Avet-Loiseau;Xavier Leleu;Murielle Roussel;Philippe Moreau.
Journal of Clinical Oncology (2010)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu.
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Arnaud Jaccard;Philippe Moreau;Véronique Leblond;Xavier Leleu.
The New England Journal of Medicine (2007)
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
Jean-Luc Harousseau;Michel Attal;Xavier Leleu;Jacques Troncy.
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
Philippe Moreau;Thierry Facon;Xavier Leleu;Nadine Morineau.
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab;Judith M. Runnels;Costas Pitsillides;Anne-Sophie Moreau.
Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
Thierry Facon;Hervé Avet-Loiseau;Gaëlle Guillerm;Philippe Moreau.
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker;Eileen M. Boyle;Christopher P. Wardell;Alex Murison.
Journal of Clinical Oncology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: